Clinical Trial Update: Dose Escalation of SNK-396 in Participants With Elevated Low-Density Lipoprotein Cholesterol [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation study evaluating SNK-396 in participants with elevated LDL cholesterol has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperlipidemia

Drugs mentioned

• SNK-396 (SNK-396)

Snippet

Sponsor: Syneos Health | Conditions: Elevated Low-Density Lipoprotein Cholesterol | Phase 1 | Status: COMPLETED